PRINCETON, N.J.--(BUSINESS WIRE)--Cytogen Corporation (NASDAQ: CYTO) today reported the publication of a seven-year survival study that suggests PROSTASCINT® may help predict which patients are less likely to benefit from brachytherapy for prostate cancer. PROSTASCINT is the first and only commercial monoclonal antibody-based agent that targets prostate-specific membrane antigen (PSMA) to image the extent and spread of prostate cancer. The study, “Biochemical disease free survival rates following definitive low dose rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT Capromab Pendetide,” by Ellis et al. appears in the online edition of the American Brachytherapy Society’s peer-reviewed journal, Brachytherapy (Brachytherapy Volume 6, Issue 1, January-March 2007, Pages 16-25.)
